SCHEMBL6474928

SCHEMBL6474928

CCN(CC)c1ccc(CCCc2cccc(Nc3ccccc3C(=O)O)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CTSV O60911 2/20 0.50
CTSL P07711 2/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
SIRT2 Q8IXJ6 5/20 0.48
PLK1 P53350 4/20 0.46
TAS2R14 Q9NYV8 2/20 0.46
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
NOX1 Q9Y5S8 1/20 0.45
FABP4 P15090 1/20 0.45
PLK3 Q9H4B4 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6484440 0.92 SIRT1 (0.48) SIRT1MEN1KMT2ACTSVCTSL
SCHEMBL6474913 0.90 MEN1 (0.55) MEN1KMT2ACTSVCTSLRECQL
SCHEMBL6475251 0.89 MEN1 (0.56) SIRT1MEN1KMT2ACTSVCTSL
SCHEMBL6474259 0.85 MEN1 (0.60) MEN1KMT2ACTSVCTSLRECQL
SCHEMBL27560782 0.84 MEN1 (0.61) SIRT1MEN1KMT2ACTSVCTSL
Hydrochloric Acid SCHEMBL6475843 0.83 MEN1 (0.60) SIRT1MEN1KMT2ACTSVCTSL
SCHEMBL6475710 0.83 CLCN2 (0.49) MEN1KMT2ARECQLBLMTDP1
Hydrochloric Acid SCHEMBL6474052 0.83 MEN1 (0.58) MEN1KMT2ACTSVCTSLRECQL
SCHEMBL6482447 0.83 MEN1 (0.53) SIRT1MEN1KMT2ACTSVCTSL
SCHEMBL6474572 0.83 MEN1 (0.48) SIRT1MEN1KMT2ACTSVCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 SIRT1 1765/4885MEN1 474/4885KMT2A 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.